本文選題：宮頸腺癌 + ZEB1��； 參考：《西南醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:觀察ZEB1(zincfinger E-boxbinding homeobox1,ZEB1)和Vimentin在正常宮頸組織(NC)、宮頸原位腺癌(AIS)、宮頸腺癌(AUC)、宮頸鱗癌(SCC)及宮頸腺鱗癌(ASCC)中的表達(dá),分析ZEB1和Vimentin在的表達(dá)及與宮頸腺癌各臨床病理參數(shù)的關(guān)系,以及二者之間的相關(guān)性,探討二者在宮頸腺癌的發(fā)生發(fā)展和侵襲轉(zhuǎn)移中的作用。為宮頸腺癌的早期診斷和早期治療提供理論依據(jù)。方法:采用Envision免疫組化法檢測ZEB1和Vimentin在各研究組織中的表達(dá)情況,其中宮頸腺癌組66例,宮頸原位腺癌12例,正常宮頸組織15例;宮頸鱗癌組45例;宮頸腺鱗癌組8例。統(tǒng)計軟件SPSS20.0用于統(tǒng)計描述與推斷,定性資料采用頻數(shù)及百分比表示,組間兩兩比較采用卡方檢驗或Fisher’s精確概率檢驗,線性趨勢資料采用線性趨勢卡方檢驗,ROC曲線下面積用于比較不同檢查指標(biāo)對宮頸癌不同病理類型的診斷價值,Spearman相關(guān)系數(shù)用于描述兩個定性資料的相關(guān)性,檢驗水準(zhǔn)α=0.05,當(dāng)P0.05時認(rèn)為差異具有統(tǒng)計學(xué)意義。結(jié)果:1、ZEB1在正常宮頸組中的陽性表達(dá)率為6.67%,在宮頸原位腺癌中的表達(dá)率為25.00%,在宮頸腺癌中的陽性表達(dá)率為75.76%;3組比較,陽性表達(dá)率逐步上升,差異具有統(tǒng)計學(xué)意義(χ2=30.147,P0.001)。其中宮頸腺癌組與正常宮頸組、宮頸原位腺癌組比較,差異顯著,有統(tǒng)計學(xué)意義(P0.05);但正常宮頸組與宮頸原位腺癌組比較,差異無統(tǒng)計學(xué)意義(P0.05)。ZEB1在宮頸鱗癌中的陽性表達(dá)率為57.78%,在宮頸腺鱗癌中的陽性表達(dá)率為87.50%,與其在宮頸腺癌中的表達(dá)比較,3組差異無統(tǒng)計學(xué)意義(χ2=5.463,p=0.065)。2、zeb1在宮頸腺癌中的表達(dá)與患者的腫瘤浸潤深度、figo分期、組織分化程度、淋巴結(jié)轉(zhuǎn)移、脈管浸潤及宮頸腺癌的病理亞型相關(guān)(p0.05),與腫瘤大小無關(guān)(p0.05)。3、vimentin在宮頸正常組織中無表達(dá),在宮頸原位腺癌中的陽性表達(dá)率為16.67%,在宮頸腺癌中的陽性表達(dá)率為27.27%;3組宮頸組織病變中的表達(dá)差異具有統(tǒng)計學(xué)意義(χ2=8.668,p=0.013)。其中僅有原位腺癌組與正常宮頸組比較差異顯著(p0.05),宮頸腺癌組與正常宮頸組、宮頸原位腺癌組比較,差異不具有統(tǒng)計學(xué)意義(p0.05)。vimentin在宮頸鱗癌中的陽性表達(dá)率為11.11%,在宮頸腺鱗癌中陽性表達(dá)率為75%,與宮頸腺癌的表達(dá)比較,3組差異顯著,具有統(tǒng)計學(xué)意義(χ2=14.424,p=0.001)。宮頸腺癌組與宮頸鱗癌組、宮頸腺鱗癌組比較,差異具有統(tǒng)計學(xué)意義(p0.05)。4、vimentin在宮頸腺癌中的表達(dá)與患者的腫瘤figo分期、組織分化程度、淋巴結(jié)轉(zhuǎn)移情況、脈管浸潤有關(guān)(p0.05),與腫瘤大小、浸潤深度、宮頸腺癌的病理亞型無關(guān)(p0.05)。5、在宮頸腺癌中,zeb1與vimentin的表達(dá)呈正相關(guān)且具有統(tǒng)計學(xué)意義(r=0.325,p0.001)。結(jié)論:1、宮頸腺癌形成過程中,伴隨有zeb1、vimentin陽性表達(dá)率逐漸升高,提示zeb1、vimentin的表達(dá)可能與宮頸腺癌發(fā)生發(fā)展有關(guān)。2、在宮頸腺癌組織中zeb1和vimentin的表達(dá)隨figo分期升高而增加,隨組織分化級別的降低而增加;提示zeb1、vimentin可能與宮頸腺癌的惡性程度有關(guān)。在宮頸腺癌中zeb1和vimentin在有淋巴結(jié)轉(zhuǎn)移組和有脈管浸潤組中呈高表達(dá),提示ZEB1、Vimentin可能與宮頸腺癌的侵襲轉(zhuǎn)移有關(guān)。3、宮頸腺癌組中ZEB1的陽性表達(dá)與Vimentin的陽性表達(dá)呈正相關(guān),提示ZEB1與Vimentin蛋白在功能上可能相關(guān),且可能存在協(xié)同作用。
[Abstract]:Objective: To observe the expression of ZEB1 (zincfinger E-boxbinding homeobox1, ZEB1) and Vimentin in normal cervical tissue (NC), cervical adenocarcinoma in situ adenocarcinoma (AIS), cervical adenocarcinoma (AUC), cervical squamous cell carcinoma (SCC) and cervical adenosscale carcinoma (ASCC). The relationship between the expression of ZEB1 and cervical adenocarcinoma and the clinicopathological parameters of cervical adenocarcinoma and the correlation between the two were observed. To explore the role of the two in the development and invasion of cervical adenocarcinoma. To provide a theoretical basis for the early diagnosis and early treatment of cervical adenocarcinoma. Methods: Envision immunohistochemical method was used to detect the expression of ZEB1 and Vimentin in various research tissues, including 66 cases of cervical adenocarcinoma, 12 cases of cervical carcinoma in situ adenocarcinoma, and normal cervix group. 15 cases, 45 cases of cervical squamous cell carcinoma group and 8 cases of cervical adenosscale cancer group. Statistical software SPSS20.0 was used for statistical description and inference. Qualitative data were expressed in frequency and percentage, 22 were compared with chi square test or Fisher 's accurate probability test, linear trend data were tested by linear trend Chi square test, and the area under ROC curve was used for comparison. The diagnostic value for different pathological types of cervical cancer was examined. The Spearman correlation coefficient was used to describe the correlation of two qualitative data, and the level of alpha =0.05 was tested. When P0.05, the difference was statistically significant. Results: 1, the positive expression rate of ZEB1 in the normal cervical group was 6.67%, and the expression rate in the cervical carcinoma in situ was 25% in the uterine cervix. The positive expression rate in cervical adenocarcinoma was 75.76%, and the positive expression rate increased gradually in the 3 groups, and the difference was statistically significant (x 2=30.147, P0.001). The difference between the cervical adenocarcinoma group and the normal cervix group and the cervical carcinoma in situ adenocarcinoma group was significant (P0.05), but there was no statistical difference between the normal cervix group and the cervical in situ adenocarcinoma group. The positive rate of P0.05.ZEB1 in cervical squamous cell carcinoma was 57.78%, and the positive rate in cervical adenocarcinoma was 87.50%. Compared with the expression in cervical adenocarcinoma, the 3 groups had no statistical significance (x 2=5.463, p=0.065).2, ZEB1 in cervical adenocarcinoma and the depth of tumor infiltration in the patients, FIGO staging, and the degree of tissue differentiation. Lymph node metastasis, vascular infiltration and pathological subtype of cervical adenocarcinoma (P0.05) were not related to tumor size (P0.05).3, vimentin was not expressed in normal cervical tissues, the positive expression rate in cervical carcinoma in situ was 16.67%, the positive expression rate in cervical adenocarcinoma was 27.27%, and the difference in the expression of cervical tissue lesions in the 3 groups was statistically significant Significance (x 2=8.668, p=0.013). Only in situ adenocarcinoma group and normal cervical group were significantly different (P0.05), cervical adenocarcinoma group and normal cervix group, cervical in situ adenocarcinoma group, the difference was not statistically significant (P0.05) the positive rate of.Vimentin in cervical squamous cell carcinoma was 11.11%, and the positive rate in cervical adenocarcinoma was 75%, The difference between the 3 groups was significant (x 2=14.424, p=0.001). The difference between the cervical adenocarcinoma group and the cervical squamous cell carcinoma group and the cervical adenocarcinoma group was statistically significant (P0.05).4, the expression of vimentin in the cervical adenocarcinoma and the FIGO staging of the tumor, the degree of tissue differentiation, the lymph node metastasis, and the pulse tube immersion. P0.05, not related to tumor size, infiltration depth, and pathological subtype of cervical adenocarcinoma (P0.05).5. In cervical adenocarcinoma, the expression of ZEB1 and vimentin is positively correlated and has statistical significance (r=0.325, p0.001). Conclusion: 1, in the process of cervical adenocarcinoma, with ZEB1, the positive rate of vimentin increases gradually, suggesting ZEB1, vimentin table. .2 may be associated with the development of cervical adenocarcinoma. The expression of ZEB1 and vimentin in cervical adenocarcinoma increases with the increase of FIGO staging, and increases with the decrease in the grade of tissue differentiation. It suggests that ZEB1, vimentin may be associated with the malignancy of cervical adenocarcinoma. In cervical adenocarcinoma, ZEB1 and vimentin have lymph node metastasis and vascular infiltration in cervical adenocarcinoma. The high expression in the group suggests that ZEB1, Vimentin may be associated with the invasion and metastasis of cervical adenocarcinoma, and the positive expression of ZEB1 in the cervical adenocarcinoma group is positively correlated with the positive expression of Vimentin, suggesting that ZEB1 and Vimentin may be related to function and may have synergistic effect.
【學(xué)位授予單位】：西南醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.33

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 吳明富;黎婧;劉麗江;;MiR-200c調(diào)控ZEB1抑制子宮內(nèi)膜癌細(xì)胞增殖和侵襲[J];武漢大學(xué)學(xué)報(醫(yī)學(xué)版);2016年05期

2 胡君;鄭佩孜;朱麗榮;;ⅠB1期宮頸腺癌和鱗癌患者保留卵巢的臨床病理特征比較[J];北京大學(xué)學(xué)報(醫(yī)學(xué)版);2016年05期

3 余劍琴;周清;鄭飛云;包影;;宮頸鱗狀細(xì)胞癌中Vimentin、Ki-67蛋白的表達(dá)及與臨床病理特征的關(guān)系[J];中華全科醫(yī)學(xué);2016年04期

4 張占薪;婁雪玲;姚麗;劉光虹;宋曉霞;田金;;E-鈣黏蛋白及ZEB1在宮頸鱗癌及宮頸上皮內(nèi)瘤變組織中的表達(dá)及臨床意義[J];中國婦幼保健;2015年25期

5 黃敬皓;;免疫組化標(biāo)記物在子宮內(nèi)膜樣腺癌與宮頸腺癌診斷中的表達(dá)及臨床意義[J];檢驗醫(yī)學(xué)與臨床;2015年06期

6 Bianca Cheaib;Aurélie Auguste;Alexandra Leary;;The PI3K/Akt/m TOR pathway in ovarian cancer: therapeutic opportunities and challenges[J];Chinese Journal of Cancer;2015年01期

7 熊艷;熊永炎;徐智高;;宮頸腺癌和子宮內(nèi)膜腺癌中hr-HPV(16/18)DNA和p16,Vimentin,ER,PR表達(dá)組型的檢測及鑒別診斷價值[J];武漢大學(xué)學(xué)報(醫(yī)學(xué)版);2015年01期

8 甘泉;蘇瑾;蔣壁謙;呂天淑;吳秀雙;;STAT3通過ZEB1調(diào)節(jié)卵巢癌細(xì)胞SKOV-3中E-cadherin表達(dá)的研究[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年11期

9 馬亞琪;王昀;劉愛軍;;WHO(2014)子宮體、宮頸腫瘤和滋養(yǎng)細(xì)胞疾病組織學(xué)分類[J];診斷病理學(xué)雜志;2014年09期

10 夏玉紅;張占薪;姚麗;程艷;宋曉霞;;宮頸癌組織中ZEB1表達(dá)及其臨床意義[J];中國實用婦科與產(chǎn)科雜志;2013年07期

相關(guān)博士學(xué)位論文 前1條

1 陳枝嵐;ⅠB-ⅡB期宮頸癌淋巴結(jié)轉(zhuǎn)移的危險分層和SNAIL、ZEB1與宮頸癌轉(zhuǎn)移相關(guān)性的研究[D];華中科技大學(xué);2012年

相關(guān)碩士學(xué)位論文 前2條

1 張玉梅;上皮間質(zhì)轉(zhuǎn)化（EMT）及其轉(zhuǎn)錄因子與宮頸癌進(jìn)展的相關(guān)性研究[D];甘肅中醫(yī)藥大學(xué)(原名：甘肅中醫(yī)學(xué)院);2015年

2 程曉曉;早期宮頸腺癌/腺鱗癌組織中Vim、CK20、CD44v6的表達(dá)及高危型HPV感染的意義[D];南昌大學(xué);2014年

，

本文編號：2008201